Yellow micropulse laser appears to be effective for chronic CSR. In every case we treated in this series, the improvement following treatment was significant. No retinal damage was seen in any of the eyes, except for minimal hyperfluorescence in one immunocompromised patient with RPE changes in both eyes prior to treatment. While most patients in our series responded well within 30 days of treatment, some may need more than one laser treatment. Long-term, prospective studies are needed to confirm the safety and efficacy of this approach.
On refractive exam, best corrected visual acuity (BCVA) can range from 20/20 to 20/ Visual loss can partly be attributed to a hyperopic shift caused by the anterior displacement of the macular photoreceptors. Folk recorded that patients with CSCR can have minimal afferent pupillary defects and reduced critical flicker-fusion thresholds, both of which are the first to improve with resolution of the CSCR episode.  Ophthalmoscopy typically discloses a round or oval serous macular detachment without hemorrhage, with small, yellow sub-retinal deposits in the area of neurosensory detachment.  At times, the sub-retinal fluid may contain grey-white serofibrinous exudate.  A RPE detachment may be seen on OCT in up to 63% of eyes  and if it encircles the detachment, a “halo” may be seen around the detachment.  Macular RPE mottling can be found in cases of recurrent or chronic CSCR. Ophthalmoscopy may show a range from mono- or paucifocal RPE lesions with prominent elevation of the neurosensory retina by clear fluid - typical of cases of recent onset - to shallow detachments overlying large patches of irregularly depigmented RPE.
The ophthalmologist or eye doctor at the hospital will make the diagnosis of CSR. The ophthalmologist will examine your eyes using a microscope called a slit lamp. In order to examine the retina and macular area more easily, your pupils will be dilated with eye drops that take about 30 minutes to work; the effect of the drops usually wears off in about 6 hours. Often further testing will be required to confirm the diagnosis of central serous retinopathy including fluorescein angiography and / or optical coherence tomography (OCT) imaging.